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Introduction 
Experiencing a spinal cord injury (SCI) 
is extremely distressing, both physically and 
psychologically, and throws people into a 
complex, unfamiliar world of medical procedures, 
terminology, and decision making. You may have 
already had surgery to stabilize the spinal column 
and reduce the possibility of further damage. You 
are understandably distressed about the functions 
you may have lost below the level of spinal injury. 
You wish to recover any lost abilities as soon as 
possible. You, your family, or friends may have 
searched the Internet for treatments and cures.
After an SCI, patients are often told that there 
are no approved drug or cell transplant treatments 
that will repair the damage and restore voluntary 
movement. This is still true, regardless of what you 
may hear or read about a research “breakthrough.” 
This advice is given with the best intentions, in the 
hope that people will focus on their rehabilitation 
and recovery programs, rather than looking for a 
miracle cure. Nevertheless, great advances have 
been made in the science of spinal cord repair. 
Treatments that could one day improve the 
function of people living with SCI are being tested. 
However, there are also people who might offer you 
an unproven treatment, claiming they can restore 
function if you have money to pay!
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This article is intended to address some of the 
questions you may have about various therapies 
or treatments after SCI, that are experimental, 
meaning their benefits and risks are still unproven 
but they are being studied by medical experts 
and researchers. The therapies discussed in this 
article are not to be confused with the approved 
medications that you might receive to manage 
infections, spasticity, or other health issues. The 
information provided focuses mostly on testing of 
new drugs, cellular therapies, tissue or cells used 
as grafts, antibodies or other biological substances, 
and newly developed technologies and devices. 
It offers advice to help you make an informed 
decision about participating in a clinical trial. It 
will also explain why you should avoid paying for 
unproven treatments and placing yourself at risk for 
an unlikely benefit. You are encouraged to discuss 
these issues with your healthcare team.
A group of leading scientists and clinicians 
contributed their time and expertise to create this 
article to help you understand how treatments are 
developed and tested and to help you make informed 
choices. It was first created in 2006, revised in 2012, 
and has now been updated as of 2021.
The first thing to understand is how experimental 
treatments become proven therapies that you can 
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What is the difference between a clinical trial and 
clinics offering unproven procedures?
The process by which science becomes approved 
medical practice is designed to minimize harm 
and maximize benefit to patients. This is a long 
but well-defined process meant to protect people 
and determine who is most likely to benefit from 
a new therapy. New drugs or cell-based therapies 
first tested in animal studies can appear to be very 
promising. However, they need unbiased, well-
constructed clinical trials to show they do not pose 
unacceptable risks and do benefit people with a 
specific injury or disorder. Unregulated use of new, 
unproven treatments based on unreliable evidence 
raises false hopes and can endanger people. Offering 
unproven therapies, not authorized by national or 
local regulators, in exchange for payment hijacks 
the processes meant to protect patients. It can 
result in patients spending large sums of money 
for no benefit, and some even experiencing serious 
complications (more on that later). That is why it is 
really important to understand if an experimental 
procedure is part of a well-designed and scientifically 
justified (i.e., valid) clinical trial before you consider 
receiving it.
How do I tell whether an experimental treatment is 
part of a valid clinical trial program?
You are curious, but hopefully cautious, and 
wish to know how to best evaluate the credibility of 
a new treatment or a clinical trial. It can be difficult 
to tell the difference between a genuine clinical trial 
and a treatment program that only claims to be a 
trial. Perhaps the easiest way to tell the difference 
is whether you must pay for the treatment being 
studied. If you are asked to pay to receive a drug 
or procedure that is still experimental, it is not a 
clinical trial! You should not be asked to pay for 
the experimental treatment itself. However, even in 
a valid trial you might have to cover standard care 
and accessory costs such as travel or rehabilitation, 
or your insurance may be charged (and your usual 
copayments or deductibles might apply).
Even though treatments that can restore the 
function lost after SCI have not been established 
yet, several clinical trials are being conducted under 
the watchful eye of governmental regulators. A 
website, SCITrialsFinder.net, has been developed to 
explain and make it easier to find and understand 
SCI clinical trials that are being conducted carefully 
and safely.
Before agreeing to participate in any well-run 
clinical trial, you must be fully informed about the 
trial and what you can expect. This means in terms 
of the treatment, follow-up appointments, etc., 
and formally consent to participate (see “informed 
consent” below). There are questions you should 
ask and answers you should expect from someone 
explaining a clinical trial or offering an experimental 
treatment. The differences between a rigorous 
clinical trial and an unproven “treatment” offered 
by a clinic claiming success of their new, “cutting-
edge” therapy can be confusing. Appendix A will 
help you ask the right questions and understand the 
answers.
Why are clinical trials necessary?
Every experimental therapy and clinical trial, 
without exception, has at least some risk of causing 
unintended complications or other potential harm 
to participants. Well-designed trials must consider 
and document both benefits to those who receive 
treatments and also unforeseen risks. It can be 
surprisingly difficult to prove if a treatment or 
therapy is safe and that it really works. If a person 
receives an experimental therapy and experiences 
some recovery, they commonly believe they got 
better as a direct result of the new treatment. 
However, the improvement may not have been the 
direct result of the treatment. There are two other 
possibilities to consider.
Spontaneous recovery and the importance of 
rehabilitation. Immediately after an SCI, some 
people are completely paralyzed below the area of 
injury. Even without restorative treatment, almost 
all will experience at least a little improvement in 
function (spontaneous recovery), which can be 
enhanced by active rehabilitation. Depending on 
the amount of damage to the spinal cord, some 
people recover more function, and a small number 
of people will achieve dramatic recovery. The rate of 
recovery is usually greatest over the first 3 months, 
but with sustained rehabilitation and effort, 
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Controversial “medical tourism” clinics that 
offer cell transplants to people may also include 
vigorous rehabilitation. Thus, for people who have 
received an unproven drug or cell transplant, it 
can be difficult to tell whether improvement is due 
to some spontaneous recovery, to the benefits of 
rehabilitation, or to the effect of the experimental 
treatment itself. Clinical trials are designed to 
determine which of these possibilities can most 
reliably explain the cause of any observed recovery.
The placebo effect. Everyone has hopes and 
aspirations, including scientists, clinicians, and 
patients. In medicine, our desires can lead us to report 
outcomes that are not the direct result of a therapy. 
Thus, even after receiving a control substance, one 
that contains no medication, a patient’s hope may 
influence their perception and lead them to report 
an improvement. Likewise, the unintended biases 
of scientists and clinical investigators can lead them 
to conclude a therapy has an apparent benefit when 
the improvement is due to some other cause.
A control group in a clinical trial is designed to 
equalize all factors and expectations that could affect 
outcomes, other than the treatment that is being 
tested. This means that by comparing two or more 
groups of people, scientists will truly see the effect 
of the experimental treatment. A placebo or “sham” 
treatment is given to a group of control subjects 
who otherwise get all the same testing and care as 
the experimental group, without letting either the 
patients or the clinicians know who is receiving the 
active treatment and who is not. While not always 
feasible, this is the most effective way to accurately 
measure whether there are actual benefits of the 
experimental therapy. In a trial, control patients 
who receive a placebo might report improvement in 
their condition, sometimes as much improvement 
as the group who received the active treatment. 
When that happens, it is only logical and reasonable 
to conclude the experimental treatment has little or 
no therapeutic benefit.
If an experimental therapy has not completed a 
properly designed clinical trial program, there is a 
real danger that treatments that do not actually work 
or even do harm could be offered. This puts patients 
at risk, and can interfere with the development and 
testing of safer, more effective treatments.
What makes a good clinical trial?
A good (scientifically sound) clinical trial 
(human study) usually will test an experimental 
“therapeutic” (a drug, cell therapy, device, etc.) only 
after it has undergone extensive study in animals, 
or in people with another related human disorder, 
and will have published evidence of safety and 
a potential for a beneficial effect. Such a clinical 
trial program has several phases (see below). It 
will be carefully designed to compare a group of 
participants receiving the experimental treatment 
with others (controls) receiving no treatment 
(or sham procedure), a placebo substance, or the 
current best standard of care. New surgical and 
rehabilitation strategies are also tested to show 
safety and that people benefit from the procedures, 
but some trial aspects, like sham procedures, may 
not be feasible or ethical in these cases. Without 
completing a clinical trial and comparing the effects 
of a treatment in the experimental group to the 
outcomes in those who do not receive the treatment, 
it is impossible to determine if the treatment safely 
provides a meaningful benefit.
Unintentional bias or self-interest on the part of 
the people who conduct clinical trials (investigators) 
can pose a significant risk for the misinterpretation 
of trial data or, even worse, can lead to short-cuts in 
the scientific process of a trial, resulting in harm to 
people. Clinical trials are designed to protect from 
this bias and be as fair as possible in assessing the 
effect of a treatment.
Blinding. When testing a new therapy that shows 
promise, people with spinal injuries, their surgeons, 
therapists, and everyone involved in SCI healthcare 
wants the treatment to improve independence, 
mobility, and quality of life. These genuine and 
compassionate desires can result in unintended 
biases and lead people to overestimate functional 
improvements or overlook possible risks. Therefore, 
it is best to “blind” both the trial participants and 
the investigators, ensuring they do not know which 
person received what treatment (experimental or 
placebo control).
Sometimes the persons administering or 
receiving a treatment must know who does or does 
not receive it. For example, surgeons will know 
what procedure they perform, and people who 
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know that they are in the experimental group. In 
these cases, at minimum, other study personnel 
who collect or analyze outcome data can and should 
be “blinded” so they do not know what treatment 
was administered to the trial participant they are 
examining.
Conflict of interest. Although clinical trial 
investigators may be reimbursed for their research, 
they should not have a direct financial benefit or 
other competing interests in the outcome of the 
trial. If an investigator could benefit financially from 
the outcomes of a human study, this is a conflict of 
interest that could be a temptation or unconscious 
bias to report a positive benefit of the treatment. 
Such conflicts can and should be carefully managed. 
Institutional Review Boards are independent panels 
that safeguard patient rights and must approve 
scientific clinical trials. They have strict standards 
for investigator disclosure of potential financial 
conflicts of interest. Patients should be made aware 
of any potential conflicts of interest situation by 
the investigators as a part of the informed consent 
process. If this is not disclosed, then it is within your 
rights to ask.
Avoid unproven treatments offered for direct 
payment. Understandably, some patients with an 
SCI want to improve, no matter the cost. That creates 
an opportunity for less scrupulous organizations to 
offer unproven treatments to those who can pay. 
You should question any request for payment of an 
“experimental” clinical trial procedure, as this is not 
allowed in scientifically valid clinical trial programs. 
Depending on your health care coverage, you, 
your private or government insurance plan may be 
expected to pay for the current standard of medical 
care you receive during your participation in a clinical 
trial, and your usual deductibles and copayments 
may apply. You should ask and be told up front what, 
if any, payment is required for your participation in a 
trial, but the experimental treatment itself and all the 
related follow-up assessments should be provided at 
no additional cost to you. 
Creating new treatments for those with spinal or 
brain injuries is one of the most difficult challenges 
medicine has ever attempted. Yes, like winning the 
grand prize in a large lottery, there is a very small 
chance that a treatment offered without completing 
a clinical trial might work, but it is much more 
likely that it will not be effective or even do harm. 
We strongly advise you to only participate in well-
designed SCI clinical trials where there is solid 
evidence of positive benefits from previous animal 
experiments or approval by regulatory agencies 
of the treatment for a related clinical disorder. 
Treatments are approved for specific groups of 
people with particular disorders, so they are not yet 
proven to be safe and effective in other populations. 
That is why there would be a need for a new clinical 
trial focused on people with SCI.
How are clinical trials structured?
An important part of most clinical trials is the 
assignment of participants to either an experimental 
treatment group or a control group, which is often 
done randomly to prevent bias. As mentioned 
above, the control group goes through similar 
procedures but does not receive the experimental 
therapy. This helps eliminate the possibility that 
many uncontrollable factors and experience of being 
part of a study could influence the participants’ 
outcomes.
Random assignment to either the experimental or 
control group helps ensure that these “other” factors 
influence the groups equally. For example, most 
people receive active rehabilitation after SCI. By 
itself, rehabilitation can improve function in people 
living with SCI, which is why we recommend you 
participate in available rehabilitation opportunities. 
Thus, without a control group that will receive a 
similar amount of active rehabilitation, any observed 
improvement seen after receiving an experimental 
treatment therapy combined with rehabilitation 
could be falsely attributed to the treatment itself.
In some cases, participants with chronic SCI 
have a very stable baseline level of function that can 
be measured before they receive the experimental 
therapy and then compared to their capabilities 
later in the trial to see if there is any improvement. 
This exception to the use of a separate control group 
can only be made if the trial is carefully designed 
so that the participants act as their own control 
without introducing bias into the results. In some 
trials, two groups are tested, one group receiving 
the experimental treatment followed by a period 
in which they receive a placebo, while the other 
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experimental treatment. Regardless, the examiners 
assessing the outcomes in such trials are blinded as 
to what was done and in what order.
Another exception relates to early clinical trials 
(Phase 1; see below for description of trial phases), 
which primarily focus on testing the safety and the 
feasibility of offering the treatment. These early 
studies are usually accomplished with a small 
number of participants and are generally completed 
without a control group. Nevertheless, a control 
group will be part of any later Phase 2 or Phase 
3 trials that test whether the treatment actually 
provides a benefit (efficacy).
As mentioned above, it is also important to 
remove bias either trial investigators or study 
participants may have. This is why trial programs 
that successfully pass Phase 1 safety evaluation 
need to be followed by trials designed to examine 
the true effect, where the investigators are blinded 
as to which group gets the experimental therapy to 
preserve the objectivity that is needed to accurately 
determine whether a treatment is safe and beneficial.
What if I get assigned to the control group?
Most people with high hopes would obviously 
prefer to receive a beneficial treatment. However, 
when studying an experimental treatment in a 
clinical trial program, we do not know whether it has 
any benefits or significant risks. As described above, 
it is impossible to learn if a treatment really works 
and is reasonably safe unless there are appropriate 
control patients with whom to make comparisons. 
If we already were certain that available evidence 
proved a treatment to be effective, it would be 
unnecessary and unethical to delay treatment by 
further testing.
By definition, ethical trials are conducted 
because the true benefit of experimental treatments 
is not known. Clinical investigators have to adopt 
a “wait and see” perspective about the risks and 
benefits, until all trial phases are completed. If by 
mischance the treatment has an undesirable or 
harmful side effect, then being in the control group 
may be an advantage! You should also consider 
that being in the control group will come with 
some added benefits such as more contact with the 
professionals and more thorough examinations that 
are not necessarily part of the standard care.
Volunteers participating in a trial, whether they 
are in the experimental or control group, should 
always receive the current best care available. The 
trial investigators will have a policy on what to offer 
members of the control group at the end of the trial, 
which may include receiving the tested treatment 
after the trial, if it is proven to be effective and if you 
still meet the eligibility criteria. If this is not made 
clear to you, you need to ask about it.
What are the various trial phases?
Clinical trials testing drugs, cell therapies, 
antibodies or other biological therapies, and some 
new devices usually require positive results in 
three separate phases (Phase 1, 2, and 3) before 
an experimental treatment will be approved by a 
government regulatory agency for use in people 
with a specific disorder (Figure 1). Each trial phase 
is more demanding than the previous one, involving 
more participants and longer term outcomes that 
demonstrate real benefit to people with that disorder, 
as well as long-term safety. You would likely only be 
involved in one trial phase, and you should be told 
where the testing stands and in which phase of the 
trial program you will be participating. 
Phase 1 is to find out if the treatment is safe and 
can be tested in humans. A fairly small number 
of participants, usually less than 50, are given the 
treatment (often at slightly different doses) to see if 
there are any unexpected, harmful side effects. This 
is the one clinical trial phase where it is common not 
to have a control group, as the emphasis is on safety 
and tolerability of the experimental treatment. Such 
trials are sometimes referred to as “open label” 
trials as everyone (participants and investigators) 
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be blinded assessments. A series of routine clinical 
tests are undertaken, and the participant is asked to 
report any discomfort or change in body function. 
Sometimes, functional activity assessments are also 
included, but conclusions will not usually be made 
about the benefit of the treatment. It should be 
noted that safety is always monitored throughout 
all clinical trial phases, but in Phase 1, it is the main 
focus.
Phase 2 is a second round of trials designed 
to assess whether the treatment stimulates the 
predicted positive biological activity within the 
body or a specific area (target tissue) or provides 
a clinically meaningful benefit by improving the 
intended body function(s). These outcomes in the 
experimental group are compared to those of a 
control group that receives an appropriate placebo 
treatment or standard of care. Because Phase 2 trials 
often involve as many as 200 experimental and 
control subjects, they frequently include multiple 
study centers.
Phase 2 trials are commonly used to determine 
the best dose and timing of treatment, as well as the 
best outcome assessments to detect and measure 
any positive (or negative) effects of a treatment. This 
phase is important to establish the best protocol for 
the next phase, a pivotal Phase 3 study. Even if the 
evidence from Phase 2 studies suggests a possible 
benefit in some of the participants, this still does not 
prove that the treatment will be reliably effective for 
others. The number of participants is still relatively 
small, and particularly good or bad results in just a 
few participants can lead to misleading conclusions.
Phase 3 is the pivotal trial phase, designed 
to more fully test the effectiveness and safety of 
the therapy. It involves the largest number of 
participants at multiple locations (often in several 
countries). This phase helps the investigators learn 
if the treatment works well enough to improve 
outcomes in a more varied population, typically men 
and women, different ages, races, etc. Furthermore, 
it helps ensure that different centers can provide 
the treatment in the same manner and equally 
well. If the treatment demonstrates a clear benefit 
with no serious side effects (adverse events related 
to treatment) then it is eligible for consideration 
of approval by a national regulatory agency as a 
treatment for the disorder being studied in the trial.
What are regulatory oversight and registration of 
clinical trials?
Scientifically valid clinical trials should be 
conducted under the oversight of appropriate 
national and local regulatory authorities. 
National authorities such as the Food and Drug 
Administration (FDA) in the United States, the 
European Medicines Agency (EMA), or Health 
Canada (HC) regulate trials testing new drugs, 
cellular therapies, tissue transplants, and new 
devices or technologies. Trials that test surgical 
procedures or rehabilitation activities may not be 
regulated by those agencies, however, all genuine 
trials are overseen and should have approval from 
the local human research ethics committee (such as 
an Institutional Review Board or IRB).
It is also important to remember that drugs, cells, 
and devices are approved to treat specific disorders, 
or segments of the population. Off-label use (e.g., 
for people with other disorders, another age group, 
pregnancy, etc.) is still a form of unproven therapy. 
Any scientific studies of these treatments should be 
done with the oversight of the proper authorities. 
Not only is this safer for the people that receive the 
therapy, but it is the only way a treatment can gain 
acceptance as a standard of care for those other 
disorders or populations.
An increasingly common practice is the 
registration of trials on a publicly available site (e.g., 
http://www.clinicaltrials.gov, https://www.who.int/
clinical-trials-registry-platform, https://anzctr.org.
au/). Registering the trial on databases such as these 
is important, but it is not an assurance that the trial 
has received the go-ahead from the proper national 
(FDA, EMA, HC) or local (IRB) oversight.
The ClinicalTrials.Gov website can serve as 
a source of valuable information for patients, 
clinicians, and scientists, but it may be difficult for 
lay-people to follow. SCITrialsFinder.net can help 
you navigate this information more easily. The 
physician investigator asking you whether you wish 
to participate in a clinical trial will provide proof 
that all national and local regulatory and ethical 
human study approvals have been obtained.
What is required for participation in a clinical trial?
Before anyone can be enrolled in a trial, they must 
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the trial and their participation will involve. This 
process, known as “informed consent” is explained 
below. Next, they are screened against a set of pre-
set criteria to see if they qualify to participate in 
that clinical study. Not all people with the disorder 
will qualify to participate in a given trial. Every trial 
should have specific conditions (called inclusion/
exclusion criteria) that must be satisfied for an 
individual to participate. Experimental therapies are 
designed to treat certain conditions and situations, 
so trials are designed to include participants that 
have those conditions and are at least risk for harm 
and most likely to benefit from the therapy being 
tested. For example, the past evidence may indicate 
a drug or cell transplant should be administered 
within a specific time window after SCI, so enrolling 
you if you are not in that stage of injury could put 
you at risk when benefit is unlikely. The location 
and severity of your SCI may or may not meet the 
eligibility requirements because of where and how 
the treatment is thought to act, the specific outcomes 
being measured, or other conditions (e.g., diabetes, 
epilepsy, etc.) that would limit your suitability for 
participation or for proper evaluation.
When an experimental treatment is being tested 
in a clinical trial, it is usually important that all the 
participants be fairly similar to each other (in terms 
of their symptoms). Too much variability between 
participants can make it difficult to show that a 
treatment has a real benefit. Like many neurological 
disorders, SCI can result in varying degrees of 
impairments, and you have probably already been 
told that your injury is classified as being at a certain 
level of your spinal cord and along a scale extending 
from complete sensory and motor loss to incomplete, 
or even minimal, sensory or motor loss. If we were 
to put all the different injury types of people with 
SCI into one study, it is likely that the different 
degrees of impairment and spontaneous recovery 
would make it impossible to determine whether an 
experimental therapy was beneficial. This is why 
clinical trial programs are often repeated for specific 
subtypes of a disorder or disease. Not qualifying for 
a trial does not necessarily mean that you would not 
ultimately benefit from the treatment being tested. 
Therefore, you might be able to obtain it later, if it is 
successful and likely to benefit someone with your 
type and stage of SCI.
What is informed consent?
Should you meet the eligibility requirements 
to participate in a clinical trial, you will be asked 
to give your informed consent. This involves a 
discussion with a trial investigator where:
1. The nature of the experimental therapy should 
be explained to you in detail, including prior 
evidence in animal studies or other clinical 
disorders.
2. You should be told about the potential benefits 
and risks of participating in the trial.
3. You should be told if you will be randomly 
assigned to either the experimental treatment 
group or the placebo control group and if your 
treatment group will not be disclosed to you 
until the study ends and is unblinded.
4. If a trial does not include a control group, you 
should be told why. Is it the phase of trial or the 
type of intervention? And what else is being 
done to ensure the results are fair and unbiased?
5. You should be informed of all study procedures, 
the duration of your participation, and what is 
required of you for follow-up visits.
6. You should be informed how the cost of any 
standard clinical care or rehabilitation, training, 
or other activities associated with the trial 
(including travel costs), will be covered.
7. You should be told if you will receive 
compensation for your participation in the trial 
and reimbursement for your expenses.
8. You should be told how any treatment or 
compensation for possible research-related 
injury will be arranged and who will pay for it.
9. You should be told how any medical 
complications you might experience will be 
handled and who will cover those additional 
costs.
10. You should be informed of the alternatives to 
participation in the clinical trial.
11. You should be informed of your right to 
withdraw from participating in the study at 
any time for any reason; you should also be 
informed that the investigators may remove 
you from the study and the possible reasons.
12. You should be given adequate time to ask 
questions and be fully satisfied that all your 
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One way to judge the quality of a clinical trial 
is the thoroughness of the informed consent 
process, the care and time that is taken to fully 
explain that you may or may not get any benefit 
from the treatment, and, especially, a description of 
all significant risks. This is particularly important 
when the long-term effects of a treatment are not 
well understood.
What if I have already received an experimental 
therapy?
People who have already participated in a 
previous clinical trial and received an experimental 
therapy for SCI (approved by regulatory authorities 
or not) may or may not be eligible to participate in 
another trial. The reason for this is that a previous 
therapy may have altered the person’s natural 
recovery and/or connections within the spinal cord 
in undetected ways, making it difficult to fairly test 
whether the current treatment has a benefit. You 
must discuss with the investigators of the current 
trial any of your past experiences with experimental 
therapies. Even if you were not accepted as a 
participant in a trial, you may be able to receive that 
treatment if and when it is approved as a treatment 
for SCI, and if it could benefit people like you (the 
approval will specify what age groups, genders, and 
types of injury the treatment is proven to benefit, 
e.g., acute versus chronic SCI).
How long will I be required to participate in the 
clinical trial?
After the informed consent process is complete 
and you have formally volunteered as a participant 
(enrolled), you are likely to be assigned to either 
the experimental treatment group or a control 
group. This assignment is likely to be a random 
process based on the rules of the trial, and you 
may or may not know whether you will receive the 
experimental treatment or the control treatment. 
Remember, blinding is important to objective 
results. If the trial is blinded, after the trial results 
have been analyzed, you can ask to find out what 
you received. Participation will include an initial 
baseline assessment to confirm your status and 
describe your capabilities at the beginning of the 
trial. During the trial, there will be some follow-up 
assessments where it will be necessary to attend the 
clinic. Clinical trials may last for different periods of 
time, depending on the type of treatment involved, 
but follow-up examinations may be required at 
intervals for several months or even a few years. 
These details should be explained to you during the 
informed consent process, but you can feel free to 
ask about them at any time.
Most trials require you to volunteer several 
hours of your time so that thorough assessments 
can be performed. Most of these examinations 
involve little or no discomfort and may include a 
physical exam, routine blood tests, and assessment 
of your capacity to perform activities of daily living. 
Imaging studies such as MRI may be carried out, 
and tests to study the connections within your spinal 
cord (conduction studies) may require electrodes to 
be placed on your skin so electrical activity can be 
measured. These evaluations are used to examine 
what changes, if any, have occurred in spinal cord 
function. You should not have to pay for these 
visits, and you should be reimbursed for travel and 
accommodation expenses if they are needed.
What should I expect after a SCI clinical trial?
As of this writing, there is still no approved 
effective treatment that restores neurological 
function for SCI. As you are already aware, the 
brain and spinal cord are the most complex tissues 
of the body and the most challenging to repair. We 
do know that some surgical procedures reduce the 
chance of further injury and active rehabilitation 
training programs can improve recovery or adaptive 
skills, especially when there is some preserved 
function below the level of spinal cord damage. 
Recent trials have revealed that surviving neural 
connections might be activated by treatments like 
electrical stimulation, but even if a new treatment 
is determined to provide some functional benefit 
after completing a clinical trial program, it is still 
unlikely that it will provide a complete cure.
Progress happens little by little, and it is most likely 
that a combination of treatments will provide better 
outcomes in the future. For example, cancer therapy 
often involves a combination of treatments, including 
surgery, drugs, and radiation therapy. It took decades 
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current cancer therapy programs. With continued 
study, scientists and clinicians will also refine the most 
appropriate combinations for SCI.
What treatments are available now?
Surgical procedures. People with SCI should 
undergo appropriate surgical procedures, if 
medically fit for the surgery, when there is clear 
anatomical and neurological evidence that the spinal 
cord has been compressed and/or the vertebral 
column is damaged and unstable. Many factors 
impact the timing of any surgery including transport 
to a hospital capable of performing the necessary 
surgery. Worldwide, there is a developing practice 
for early surgical decompression of the compressed 
or contused (bruised) spinal cord (preferably within 
24 hours of injury). Many surgeons agree that 
fractures of the vertebral spinal column should be 
stabilized, which may involve the insertion of rods 
and screws to properly align the vertebral column or 
fuse adjacent vertebrae to strengthen the vertebra, 
promote bone regrowth, and reduce the likelihood 
of further SCI in the future. During this procedure 
the abnormal pressure on the spinal cord and spinal 
nerves should be reduced, maximizing the potential 
for recovery. For more details on these and other 
treatments, please see http://www.elearnsci.org.
Rehabilitation strategies and assistive devices. 
Many SCI are incomplete and slightly asymmetrical, 
which means there is some residual function below 
the level of spinal damage, and it may not be equal on 
both sides of the body. This spared capability could 
be retention of some sensory feeling (e.g., detection 
of a pin prick) or ability to move some muscles (e.g., 
raise a shoulder, move a finger, or wiggle a toe). In 
an effort to maximize functional recovery after SCI, 
a variety of active rehabilitation strategies have been 
developed. These build upon and extend remaining 
functions, including repetitive voluntary movement 
training, strength training, and constraint use 
therapy (e.g., where someone is prevented from 
using their better functioning arm to force the 
use of the weaker one). Some muscle movements, 
such as hand function or diaphragm contractions 
(to power breathing), have been enhanced by 
functional electrical stimulation (FES) of specific 
nerves or muscles.
Thus, there is an emerging agreement that active 
rehabilitation after SCI is important and effective 
in preserving body functions, as well as improving 
the recovery of functional activity. By active 
rehabilitation, we mean activities that involve the 
individual contributing their voluntary efforts to 
the performance of the task. Passive rehabilitation 
therapy might include massage and the movement 
by a therapist or caregiver of a person’s limbs 
through its entire normal range of motion. Passive 
rehabilitation is likely to be a part of any treatment 
protocol, but is unlikely to be sufficient to maximize 
functional outcomes after SCI.
Overall, most healthcare providers believe 
that any active rehabilitation is better than no 
rehabilitation. Active rehabilitation (physical, 
occupational, or psychosocial) is likely to magnify 
the benefits from any other therapeutic intervention 
for improving outcomes after SCI, including any drug 
or cell transplant. In addition, active rehabilitation 
maintains bone and muscle integrity, fitness, and 
reduces ongoing medical complications after SCI.
Once again, if an individual is medically stable 
and will not suffer any negative effects due to 
the movements associated with the therapeutic 
activities, then rehabilitation training can be started 
soon after SCI. There are an extensive number of 
activity-dependent rehabilitation studies and trials 
underway. Although there are too many to cover 
here, scireproject.com provides detailed discussions 
of the strengths and limitations of the many 
rehabilitation strategies; please consult the SCIRE 
(Spinal Cord Injury Rehabilitation Evidence) 
chapters, which are available as a free download 
(www.scireproject.com/). Do not hesitate to discuss 
active rehabilitation strategies with your therapist 
and/or physician.
Drug and other therapies. Several currently 
available drug treatments can reduce spasticity 
and pain, or improve metabolic functions, as well 
as provide better management of bladder, bowel, 
respiration, and cardiovascular activity. There are 
also programs to help people living with SCI have 
children. Engineers have developed a number of 
assistive devices to provide improved motor function 
and increase mobility within the community.
Although these issues are of equal or greater 
importance to the quality of life for people living 
with SCI, it is beyond the scope of this article 
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medical challenges and community participation 
after SCI. As mentioned above, SCIREproject.
com presents the published evidence for SCI 
treatments that have gone through clinical trials. 
Your health care professionals can advise and guide 
you. SCIREproject.com/community/ provides 
information about SCI research that is written in 
everyday language.
What are some of the current experimental 
treatments proposed for SCI?
With all that has been discussed so far, what is 
the current state of experimental treatments for 
SCI? Potential therapeutic interventions (new 
drugs, cell transplants, rehabilitation strategies or 
assistive devices) are directed to one or more of 
several target categories:
•	 Neuroprotection:	 limiting	 the	 amount	of	 tissue	
damage and rescuing injured cells to keep 
them from dying in the hours or possibly days 
following the injury
•	 Neuroplasticity:	 facilitating	 the	 formation	 of	
new functional connections between surviving 
cells and/or replacement cells, thereby enabling 
recovery of function through the creation of new 
circuits
•	 Repair/Regeneration:	 reducing	 long-term	
damage to the injured cord, promoting new 
growth and connections from spinal neurons, 
possibly replacing lost cells to rebuild the 
damaged spinal cord
•	 Replace/Assist	 function:	 using	 an	 assistive	
(engineered) device to improve independent 
activity and/or mobility
Researchers around the world are working 
hard to develop new treatments to achieve the 
above aims. Some treatments are showing promise 
in animal experiments, and a few are already in 
early stage clinical trials (for more details visit 
SCITrialsFinder.net).
Should I still consider receiving an unproven 
treatment outside of a clinical trial?
You now possess the knowledge to understand 
why the efficacy of a potential treatment can only 
be assessed with the right tools, meaning a properly 
designed set of trials. If you still plan on receiving 
an unproven and inadequately tested treatment 
at a clinic claiming success, you need to consider 
that you will pay for a treatment that will most 
likely bring you no improvement. However, you 
must also consider your safety and possible adverse 
effects. These are usually not tracked at such clinics 
or reported to regulatory authorities so you should 
be very cautious; claims that an experimental 
treatment has no risks should raise your suspicions.
You might feel there is nothing to lose from 
trying something new, even if it is not proven. 
Unfortunately, most of the unproven treatments 
for sale throughout the world carry very little 
likelihood of actual benefit, very real risks, and at 
high financial costs. Complications may create new 
health problems. Those might be transitory, but 
there is a chance of losing further functions, causing 
pain or even life-threatening problems. In a number 
of cases, independent observers have later reported 
serious complications in some of the people who 
received unproven treatments. For example, there 
are now several reports of patients who developed 
a tumor after receiving an experimental stem cell 
transplantation into their spinal cord (Dlouhy BJ et 
al., 2014; Woodworth CF et al., 2019). A survey of 
a large group of neurologists (Julian K et al., 2020) 
in the United States found that “complications 
of stem cell tourism can be severe, and they are 
under-reported.” There are some published reports 
available that you can read and discuss with your 
healthcare providers.
What if I read about it in the media?
It can be hard to tell the difference between a 
clinical trial being conducted responsibly and a 
clinic trying to sell you unproven treatments. One 
thing to look at is the way the treatment is marketed. 
Unproven treatments are usually advertised directly 
to patients, often through persuasive language 
on the clinic’s website, Facebook, or other media 
platforms. These clinics frequently overstate 
the benefits of their treatment and use patient 
testimonials to support their claims rather than 
trial results published in clinical journals. As we 
described earlier, perceived improvement may be 
due to other factors than the advertised treatment, 
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rehabilitation, healthy lifestyle changes adopted 
along with the treatment, or other factors. One 
should question such hand-picked testimonials and 
consider how biased a view they present.
You might also read about the great promise 
of a new laboratory finding, saying a drug or 
cell therapy helped animals with spinal injuries. 
These are important findings, but a long way from 
changing clinical practice. There are many steps 
remaining to learn whether these could be safely 
tested in humans and determine if they are effective 
in helping people with SCI. During testing, the new 
therapy might need to be significantly refined, and 
in the end, it may be discovered that it has some 
benefit but comes with unacceptable risks. As much 
as successes in the laboratory are welcome, it is a 
mistake to jump too quickly to assuming they will 
lead to a new therapy.
Where can I get good advice? 
Reliable information is always the goal. You have 
a number of avenues you can explore. Whatever 
path you choose to follow, you should confirm all 
information from more than one source. Some of 
your options are:
•	 You	 can	 discuss	 your	 options	 with	 your	
physician(s).
•	 You	 can	 visit	 several	 kinds	 of	 websites,	 which	
provide a variety of information. There are 
several professional societies, nongovernmental 
spinal cord foundations, government agencies, 
and university or hospital-based research centers 
where you can seek advice. Many of them are 
staffed by people who themselves have SCIs.
•	 You	can	study	the	available	published	scientific	
and clinical literature. This may seem obvious, 
but it can also be intimidating if you don’t have a 
biomedical research background. Nevertheless, 
the most important question you ever learned in 
life was the question  “Why?”
•	 Keep	reading	and	keep	asking	questions.	Earlier	
versions of this article had a more extensive 
discussion of the above topics (some might say 
too detailed a description). However, the 2012 
version is still available at the ICORD website 
(http://www.icord.org).
•	 You	can	find	up-to-date	information	about	ongo-
ing clinical trials by visiting SCITrialsFinder.net. 
Disclaimer
This guide is based on published scientific 
papers and the professional opinions of the authors 
as of the time of writing (2021). The fundamental 
purpose and content are similar to previous 
versions (2004, 2012) of this document. Earlier 
versions, including translations of the original 
version into French, Spanish, German, Japanese, 
Chinese, and Turkish, are available at https://icord.
org/research/iccp-clinical-trials-information/. The 
recommendations are subject to change as new 
knowledge becomes available. This document is 
intended to be an additional resource for you and is 
not intended to substitute for the advice and direction 
of your health care provider or replace current clinical 
treatments. Users of this guide should periodically 
review the material to ensure that the advice herein 
is consistent with protocols of any experimental 
treatment being offered to improve functional 
outcomes after spinal cord injury.
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Appendix A
What to ask before taking part in a clinical trial or human study? (your participation checklist)
Note: Most of these questions should be answered during the informed consent process.
Question Yes No Additional Information
1. Safety   
a. Are there safety risks associated with this 
experimental treatment?   
b. Could my condition or my health get worse 
after this experimental treatment?  
c. If so, can you describe the possible risks 
associated with this experimental treatment? 
2. Possible benefits   
a.  Can you describe the possible specific benefits 
of this experimental treatment?  
b. Can you describe the maximum level of 
recovery I might see after this treatment? 
c.  Can you describe how any potential benefit 
will be measured?   
3. Clinical trial protocol   
a. Is this study being conducted under the 
oversight of an appropriate qualified 
regulatory body? 
b. Can you describe what clinical trial phase 
this particular trial falls within (Phase 1, 2, or 
3), and what is the emphasis of study for this 
phase of the trial program? 
c. Is there a control group in this study? 
d. Could I be randomly assigned to the control 
group? 
e. Can you tell me how long I will be assessed 
for any change in outcome?   
f. Will I be blinded to whether I have received 
the experimental or control treatment? 
g. Will the investigators and examiners be blind 
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Question Yes No Additional Information
4. Payments and costs    
a. Do I have to pay for the experimental 
treatment?  
b. As a possible participant, are there other costs 
I have to pay to be involved in this study?
c.  Will my expenses associated with 
participating in this study be paid (e.g., travel 
to center for follow-up assessment)?
5. Participation in other trials   
a. Will my participation in this trial limit my 
participation in other SCI clinical trials? 
b. If I am assigned to the control group and 
the experimental treatment is subsequently 
shown to be an effective therapy for my type 
of SCI by this clinical trial program, will I be 
eligible to receive this treatment later?
6. Preclinical or prior clinical evidence 
a.  Can you describe the preclinical or 
prior clinical evidence that indicates this 
experimental treatment might be beneficial?
b. Have these findings been independently 
confirmed by other researchers?
c. Are there specialists that disagree with 
the validity of this trial? What are their 
objections?
7. Independent assessment of the treatment 
and investigator
a.  Can you provide me several names of 
scientists and clinicians (not involved with 
this study) who can provide me independent 
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What should the answers be?
So what do we, the authors, say should be the 
general answers to these questions? Please see 
below, but regardless of our opinion, it is a personal 
decision for which the individual living with SCI has 
to weigh the possible benefits against the possible 
risks in determining their course of action.
1. Safety
a. Are there safety risks associated with this 
experimental treatment?
 Answer: YES; no one can guarantee total safety, 
but some information should be available about 
possible risks based on either animal data or 
earlier phase clinical trials.
b. Could my condition or my health get worse after 
this experimental treatment?
 Answer: YES; if someone tells you there are no 
risks you should be wary. However small the 
chances, there is always the possibility of some 
problem.
c. If so, can you describe the possible risks associated 
with this experimental treatment?
 Answer: The investigator should be willing to 
discuss in detail the possible risks.
2. Possible benefits
a. Can you describe the possible specific benefits of 
this experimental treatment?
 Answer: The investigator should give you a 
range of possible benefits, from very subtle to 
more noticeable functional changes you might 
or might not experience.
b. Can you describe the maximum level of recovery I 
might see after this treatment?
 Answer: Anyone who claims you are going to 
make a dramatic recovery with the return of 
almost full function should be avoided, as there 
is no evidence for any treatment having such 
striking outcomes.
c.  Can you describe how any potential benefit will be 
measured? 
 Answer: The investigator should be able to 
describe all the different kinds of tests you 
will undergo to evaluate your progress after 
treatment.
3. Clinical trial protocol
a. Is this study being conducted under the oversight 
of an appropriate qualified regulatory body?
 Answer: YES; the investigator should be able 
to provide you the details immediately. Be 
concerned if the answer is vague or consists of 
excuses why not.
b. Can you describe what clinical trial phase this 
particular trial falls within (Phase 1, 2, or 3), and 
what is the emphasis of study for this phase of the 
trial program? 
 Answer: The answer should be immediate, 
understandable, and in as much detail as you 
want.
c. Is there a control group in this study?
 Answer: YES, especially for drug and cell therapy 
trials. If not, is this a Phase 1 open-label study 
(safety only)? If not, then you should be wary. 
However, in a rehabilitation study involving 
people who have lived with a SCI for many 
months or years, the focus may be on changes 
from a baseline for the individual established 
during the trial, and a separate control group 
might not be included.
d. Could I be randomly assigned to the control group?
 Answer: YES for Phase 2 and 3 trials. If not, then 
this is likely not a scientifically strong clinical 
trial.
e. Can you tell me how long I will be assessed for any 
change in outcome?
 Answer: This could vary widely, from days or 
weeks to as much as a year or more, depending 
on the treatment and its expected effect on 
your recovery and safety. It is possible that you 
may have to commit the most time during the 
first few weeks, and this may include hospital 
stay as an in-patient. Subsequently, you may be 
asked to return for assessments at defined times 
over the following months. Once you agree to 
participate, you should be willing to complete 
the full trial protocol, even if you feel you are not 
benefiting. Participants who withdraw from a 
study undermine the completion of the trial in a 
timely fashion and make it difficult to accurately 
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f. Will I be blinded to whether I have received the 
experimental or control treatment?
 Answer: If physically and ethically possible in 
Phase 2 and 3 trials, the answer should be YES. 
If not, it could be an open-label Phase 1 trial or a 
rehabilitation or surgical trial where blinding is 
not possible or safe. In other cases, you should be 
wary. Sometimes you cannot help but know what 
group you are in, but the investigators should ask 
you not to tell the examiners which group you 
are in until the trial is over and all of the data are 
analyzed.
g. Will the investigators and examiners be blind to 
what treatment I have received?
 Answer: This should be a definite YES, for 
trial staff who can refrain from knowing the 
treatment being administered. If not, it may not 
be well-designed trial to determine the therapy’s 
effectiveness without bias, and you should be 
suspicious.
4. Payments and costs
a.  Do I have to pay for the experimental treatment?
 Answer: This should be NO. If Yes, then this 
is not a clinical trial you can trust. You should 
be suspicious and should avoid the offered 
treatment.
b. Are there any other costs associated with my 
participation in this study?
 Answer: You should not have to pay for any 
procedure specifically related to a clinical trial 
program, but you, or your healthcare insurance 
provider, may have to pay for the current standard 
of medical care. You should be informed about 
whether the trial sponsor will pay for treatment 
of any complications you might experience 
because of your participation in the trial.
c. Will my expenses associated with participating in 
this study be paid (e.g., travel to center for follow-
up assessment)?
 Answer: The answer should be YES.
5. Participation in other trials
a. Will my participation in this trial limit my 
participation in other SCI clinical trials?
 Answer: This could be a possibility unless the 
potential effect of the treatment being tested is 
known to be temporary. The investigator should 
be able to outline which type of trials you may 
be excluded from in the future. For example, 
it is unlikely that participation in an acute 
treatment trial would later affect your potential 
participation in a study at a later (chronic) time 
point. Nevertheless, the number of inclusion and 
exclusion criteria for any two trials is difficult to 
predict and compare.
b. If I am assigned to the control group and the 
experimental treatment is subsequently shown to 
be an effective therapy for my type of SCI by this 
clinical trial program, will I be eligible to receive 
this treatment later?
 Answer: This is a possibility, unless your SCI 
condition changed, or there was a limited time 
for treatment after SCI that will have passed. 
Generally, once an experimental treatment has 
been approved by a regulatory agency for clinical 
use, you would be eligible for treatment.
6. Preclinical or prior clinical evidence
a. Can you describe the preclinical or prior clinical 
evidence that demonstrates this experimental 
treatment is beneficial?
 Answer: The investigator should be able to 
describe the previous evidence in terms you 
can understand, including the strengths and 
limitations of the treatment approach. Evidence 
may come from animal studies or a related 
human disorder. Remember that effects in 
animals, such as recovery of walking, cannot be 
expected to translate directly to effects in human 
beings.
b. Have these findings been independently replicated?
 Answer: This could go either way, but there 
should be some evidence that other researchers 
have obtained similar results, confirming 
the potential benefit when investigating this 
therapeutic target or treatment approach.
c. Are there specialists that disagree with the validity 
of this trial? What are their objections?
 Answer: The answer here may be YES, as there 
are almost always some difference in opinions 
about any proposed human treatment. Scientists 
are usually very critical of each other! The 
investigator should be able to provide you with a 
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compared to any alternatives, but be wary of any 
treatment that is claimed to have no limitations. 
You, your friends, and family will undoubtedly 
use the Internet to look up information. If 
you run into biological or medical terms that 
you don’t understand, we have tried to help by 
providing a glossary of some of the relevant 
terms (Appendix B). In any case, you should 
discuss your concerns and aspirations with your 
healthcare providers.
7. Independent assessment of the treatment and 
investigator
a. Can you provide me several names of scientists 
and clinicians (not involved with this study) who 
can provide me independent advice about this 
treatment?
 Answer: The answer should be YES, and you 
should be able to verify the credibility of the 
study and the credentials of the investigators via 
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Appendix B
Experimental Treatments for SCI – Summary
Note: This section summarizes the most important 
aspects of the document. However, we strongly 
recommend that you read the entire document to fully 
understand it. Reading this section alone will not provide 
you with the necessary knowledge to make an informed 
decision that could have consequences on your well-
being.
What is the difference between a clinical trial and 
clinics offering unproven procedures?
Clinical trials are well-designed, objective tests of 
experimental treatments. They are regulated by local 
and governmental authorities and follow a defined 
scientific process to protect you from possible 
harm and to discover if the therapy is beneficial. 
Clinics offering unproven medical procedures do 
not follow these rules and cannot provide objective 
evidence the treatments they sell will work and not 
cause harm.
How do I tell whether an experimental treatment is 
part of a valid clinical trial program?
The article will explain the trial process and guide 
you on how to get more information. For a start, 
you should not be asked to pay for the experimental 
treatment being tested in a regulated, scientific trial. 
You may incur some expenses, such as insurance 
copay fees, deductibles, or accessory costs (e.g., 
travel), but the cost for the treatment being tested is 
covered by the trial sponsors.
Why are clinical trials necessary?
Clinical trials are designed to provide clear 
evidence that a treatment is safe and beneficial. 
Every experimental therapy and trial poses some 
risk of causing unintended complications. Well-
designed clinical trials document both benefits and 
unforeseen risks and are structured to determine 
if any benefit is due to the treatment rather than 
other factors, such as natural recovery or additional 
rehabilitation used along with the experimental 
treatment.
What makes a good clinical trial?
This depends on the trial phase (as explained in 
this section of the article). To test if a treatment is 
effective, a properly designed clinical trial follows a 
strict, scientifically accepted process that generally 
compares a group that receives the experimental 
treatment to a control group that gets an inactive 
(placebo) treatment. Other aspects of the trial 
should be as similar as possible for both groups. To 
remove bias or conflict of interest, trial assessors 
and participants may not be allowed to know 
which treatment has been delivered (this is called 
“blinding”).
How are clinical trials structured?
Each phase of well-designed clinical trials is 
governed by local, regional, and/or federal agencies 
that review the evidence. They ensure that the 
requirements of each phase of the process have 
been followed, and that participants have not been 
harmed by the experimental treatment, before 
allowing the next phase to proceed.
What if I get assigned to the control group?
Trials are conducted because we do not yet 
know if an experimental treatment is beneficial or 
potentially harmful. Comparisons, such as between 
people who get a treatment or do not, help avoid 
bias so that impartial conclusions can be made. 
Volunteers participating in a trial, whether they are 
in the experimental or control group, should always 
receive the current best care available. Many trials 
will eventually offer the treatment to the control 
group if it is determined that the benefit to them, 
based on the current status of their injury, outweighs 
the risks.
What are the various trial phases?
Clinical trial phases are defined by regulatory 
authorities for testing, and ultimate approval, of 
new drugs, cellular therapies, and devices. Testing 
usually requires a series of trials in sequential phases 
(Phase 1, 2, and 3) with results that indicate both 
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agency will consider approving an experimental 
treatment for use in regular care. Unfortunately, it 
is quite common to see an experimental treatment 
fail, even when early signs showed great potential. 
Short-cutting these processes will likely result in a 
failure.
What are regulatory oversight and registration of 
clinical trials?
National authorities regulate trials testing new 
drugs, cellular therapies, tissue transplants, devices, 
or technologies. Trials that test surgical procedures 
or rehabilitation activities may not be regulated by 
those agencies. However, all genuine trials should 
have approval from the local human research ethics 
committee. Treatments are approved for specific 
disorders, or segments of the population, so off-
label use is still a form of unproven therapy. An 
increasingly common practice is the registration 
of trials on a central, public website, which is 
not a substitute for regulatory approval. The 
trial investigator will be able to inform potential 
participants about the registration details and 
agency approval associated with the trial.
What is required for participation in a clinical trial?
A well-designed trial, especially in the early 
phases, needs to limit testing to a group of 
participants who are similar to each other in order 
to have the best chance to show a benefit. Therefore, 
a person interested in participation must match a set 
of criteria (called inclusion and exclusion criteria) 
that is determined before the trial is allowed to 
proceed.
What is informed consent?
Before you participate in any trial activities, 
all aspects of the trial must be explained to you, 
including what is being tested and how, what is 
expected of you, and all potential risks and benefits, 
both short- and long-term. This occurs via a 
thorough discussion with the investigator during 
which you may ask any and as many questions as 
you wish. Only when you feel all your questions 
have been answered to your satisfaction will you 
be asked to sign the form that says you have been 
informed and give consent to participate.
What if I have already received an experimental 
therapy?
Having already received an experimental therapy 
may or may not disqualify you from receiving 
another experimental therapy. This depends on 
what the previous experimental therapy was and 
how it might interact with the next experimental 
treatment. This can only be determined on a case-
by-case basis, in discussion with the investigator of 
the trial that you are considering.
How long will I be required to participate in the 
clinical trial?
You will become a volunteer participant (e.g., 
be enrolled) once you have given your informed 
consent. After that, the length of time you participate 
depends on the trial but typically involves several 
hours (during each of several visits) over several 
weeks, months, or even longer. You are free to 
withdraw your consent and stop participating at 
any time and for any reason.
What treatments are available now?
Surgical procedures, rehabilitation, drug 
therapies, and assistive technologies, including 
some types of electrical stimulation, are currently 
used in standard care. Surgical decompression and 
stabilization of the bones of the spinal column very 
soon after spinal injury are accepted best practices 
in many places around the world. Surgery is also 
indicated to treat complications including cysts 
expanding within the spinal cord (syringomyelia) 
that can cause loss of sensation or motor function, 
pain, and autonomic disturbances in 5% to 
10% of people with chronic SCI. Many forms of 
rehabilitative strategies administered by trained 
therapists are standard practice, some including 
assistive technologies or functional electrical 
stimulation to maximize functional recovery. SCIRE 
(www.scireproject.com) provides information 
about accepted rehabilitation strategies as well 
as drugs currently approved to treat spasticity, 
pain, metabolic functions, and management of 
bladder, bowel, respiration, cardiovascular, sexual, 
reproductive activity, bone health, community 
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What are some of the current experimental 
treatments proposed for SCI?
Current potential therapeutic interventions (e.g., 
new drugs, cell transplants, rehabilitation strategies, 
or assistive devices) are focused on neuroprotection, 
repair/regeneration, neuroplasticity, and 
replacement/assistance of function. More details 
can be found at SCITrialsFinder.net.
Should I still consider receiving an unproven 
treatment outside of a clinical trial?
This is a personal choice, and the information 
provided here will help you to decide. If you choose 
to receive an inadequately tested treatment at a 
clinic claiming success, you may pay for a treatment 
that will most likely bring you no improvement 
and possibly cause adverse effects. You may need 
to undergo extensive travel with its attendant risks. 
Complications may create new health problems, 
and there is a chance of losing further functions, 
causing pain, or even life-threatening problems. 
You should discuss these with your healthcare 
provider(s) before making a final decision.
What if I read about it in the media?
Regulatory agencies strictly control marketing of 
experimental treatment trials; however, clinics that 
sell unproven treatments often advertise directly 
to patients through clinic websites, brochures, and 
social media platforms. Positive results from trials 
of experimental treatments are published in peer-
reviewed journals while clinics selling unproven 
treatments mainly provide selected testimonials, 
questionable data, and lack oversight by regulatory 
agencies.
Where can I get good advice?
Good advice is available through your medical 
professionals, nonprofit organizations (professional 
societies, government and nongovernmental 
organizations, foundations, academic or medical 
research centers, and advocacy groups), as well 
as published clinical and scientific literature in 
reputable medical journals.
Appendix A: What to ask before taking part in a 
clinical trial or human study?
A participation checklist, with questions that 
you can ask during the informed consent process, is 
available in Appendix A, along with information to 
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Appendix C
Glossary of Selected Biomedical Terms
Note: These terms are commonly used in the 
discussion of spinal cord injury (SCI) and/or 
experimental treatments after SCI. They are provided for 
your reference, but we could not include every medical 
or biological term you might encounter.
Activities of daily living (ADL): activities involved 
in self-care, bowel and bladder management, and 
mobility, such as bathing, dressing, eating, and 
other skills necessary for independent living
Ambulation: walking, with or without the use of 
assistive devices such as a walker or crutches
ASIA (American Spinal Injury Association): 
a North American based society of physicians, 
surgeons, scientists, and other allied health 
professionals who treat or investigate SCI. For 
more information, see ASIA’s website: www.asia-
spinalinjury.org.
ASIA Impairment Scale (AIS): (sometimes referred 
to as ASIA Grades) describes the completeness or 
severity of a spinal injury. A booklet and training 
manual is published and made available by ASIA 
(see above).
AIS A: no motor or sensory function below the 
neurological level of injury and all the way down 
to the end of the spinal cord (at the level of S4-S5 
sacral segments). Also known as ASIA A.
AIS B: some sensory function below the 
neurological level of injury, including S4-5, but 
no motor function. Also known as ASIA B.
AIS C: some motor function below the 
neurological level, but half or more of the key 
muscles involved have a muscle strength score of 
less than 3, which is classified as nonfunctional. 
Also known as ASIA C.
AIS D: motor function below the neurological 
level, but half or more of the key muscles have a 
muscle grade of 3 or more, which is classified as 
functional. Also known as ASIA D.
AIS E: normal motor and sensory function. Also 
known as ASIA E.
Assistive, adaptive, supportive devices: a variety 
of implements or equipment used to aid individuals 
in performing tasks or movements
Bias: Consciously or unconsciously, the desire to find 
a therapy beneficial can prejudice the interpretation 
of trial outcomes. This will lead to conclusions that 
do not reflect the true benefit or harms caused by a 
treatment, or ignore the impact of other factors. Bias 
in the design, conduct, analysis, and interpretation 
of a clinical trial can falsely increase the perceived 
benefits while overlooking risks.
Blinded assessments: those evaluations conducted 
on a clinical trial subject where the evaluator 
does not know whether the subject is part of the 
experimental or control group. Blinded assessments 
are considered important to reduce any bias in the 
analysis of the effects of an experimental treatment. 
There are different levels of blinding:
Single-blind: either the clinical investigator or the 
subject, but not both, are blinded. 
Double blind: Neither the participating trial 
subject nor the investigators, institutional 
staff, or sponsoring company are aware of the 
treatment each subject has received during the 
trial. Information regarding which treatment 
was assigned to each individual will typically 
be held securely by responsible independent 
members of the study center (or the central data 
center). It will not be matched with the data (trial 
outcomes) until after the study is completed.
Clinical Trial: a human research program that 
will examine the effectiveness and/or safety of a 
therapeutic intervention. Prior to issuing a license 
for a new treatment of a disorder, a typical clinical 
trial program contains studies at three different 
stages or phases: 
Phase 1 is to find out if the treatment is safe. 
Subjects are given the treatment (often at slightly 
different doses) to see if there are any unexpected, 
harmful side effects. 
Phase 2 is the second preliminary study designed 
to assess whether the treatment provides a 
clinically meaningful benefit, to further explore 
safety and perhaps dosing.
Phase 3 is the pivotal trial phase to test the 
effectiveness and safety of the therapy and 
involves the largest number of participants, 
usually at multiple locations. If the treatment 
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effects (adverse events), then it is eligible to be 
considered for approval by a national regulatory 
agency as a clinical treatment for the disorder 
being studied.
Complete and incomplete SCI: terms used to 
describe the overall severity of SCI. Technically, 
SCI is classified as complete if there is no motor or 
sensory function preservation in the sacral (most 
caudal) spinal segments. Thus, incomplete SCI is 
when there is some preserved motor or sensory 
function at the lowest sacral spinal level (S4/5). 
There can be extensive variability in the degree of 
preserved function after incomplete SCI.
Control: the comparison group in a clinical trial, 
which does not receive the experimental treatment 
being investigated. The control group may receive 
a placebo (inactive substance), another treatment, 
or no treatment. The outcomes of the experimental 
treatment group are compared to the outcomes 
of the control group. The use of a control group 
enables researchers to determine whether the new 
experimental treatment provides a statistically 
significant and clinically meaningful (functional) 
benefit for the treatment of SCI.
Electrophysiological testing: the process of 
examining the effects of electrical, magnetic, or 
natural stimulation. Electrophysiological testing can 
be very informative for examining nervous system 
function, particularly the connectivity across the 
damaged spinal cord.
Frankel Scale: an earlier scale for classifying 
severity of spinal cord injury that was modified in 
1992 to create the ASIA Impairment Scale or AIS 
(see above).
Functional electrical stimulation (FES): treatment 
through the application of electricity to the 
peripheral nerves that arise from the spinal cord. 
One application would be FES of specific peripheral 
nerves to train and enable a weak or paralyzed 
muscle to now make a functional and purposeful 
movement (e.g., phrenic nerve FES for breathing).
Functional Independence Measure (FIM): records 
the severity of disability in people after a disabling 
disorder based on 18 items. Thirteen items define 
disability in motor functions. Five items define 
disability in cognitive functions. FIM was not 
specifically designed for any single disability such 
as spinal injury. The Spinal Cord Independence 
Measure (SCIM) was designed to specifically record 
capacities after spinal cord injury (see below).
Functional recovery/improvement: an 
improvement in the ability to perform a physical 
action, activity, or task. Some degree of functional 
recovery is expected to occur spontaneously after 
injury, but this may be very limited, particularly in 
sensorimotor complete (AIS A) SCI.
Incomplete SCI: see Complete and incomplete SCI.
International Standards for Neurological 
Classification of Spinal Cord Injury (ISNCSCI): 
A detailed neurological assessment forms the basis 
for the International Standards for Neurological and 
Functional Classification of Spinal Cord Injury (the 
ASIA International Standards). They are conducted 
on subjects lying on their backs and involve a 
grading of sensory responses to touch and pin prick 
at each of 28 areas along each side of the body and 
a grading of the strength of contraction within 10 
representative (key) muscles.
Motor score: based on the ISNCSCI assessment of 
muscle strength. The motor score is calculated by 
assigning to the muscle group a score between 0 (no 
detectable contraction) and 5 (active contraction 
against resistance considered to be normal with 
a full range of movement). C5 to T1 and L2 to 
S1 are tested, giving 10 levels on each side of the 
body for a possible maximum score of 100. The 
Lower Extremity Motor Score (LEMS) is a maximal 
50-point set of the ASIA motor score for the leg and 
foot muscles. The Upper Extremity Motor Score 
(UEMS) is a maximal 50-point set of the ASIA 
motor score for the arm and hand muscles.
Motor Level: defined as the most caudal (lowest) 
spinal level having a muscle strength of 3/5 or 
greater while all key muscles above are normal (5/5).
Neurological level of spinal cord injury: generally, 
the lowest segment of the spinal cord with normal 
sensory and motor function on both sides of the 
body. However, the spinal level at which normal 
function is found often differs on each side of the 
body for both sensory and motor functions. Thus, 
up to four different segments may be identified in 
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The level of spinal column (bone) injury may not 
correlate with the neurological level of spinal cord 
injury.
Open label: both the researcher and the trial 
participant know the treatment that the participant 
is receiving.
Paraplegia: the term used to refer to functional 
loss below the level of the upper extremities, which 
may involve loss of motor and/or sensory function 
within the trunk and/or lower extremities (legs). 
This implies damage to the spinal cord below the 
level of T1.
Peer review: a process by which experts in the same 
field (peers) evaluate the results of a study or trial. 
This ensures both quality and validity.
Preclinical: the term used to describe scientific 
experiments conducted prior to a human clinical 
trial and may include in vivo studies of animal 
models of the disorder or examination of cells in an 
in vitro culture situation.
Placebo: an inactive substance or treatment that has 
the same appearance as the experimental treatment 
but does not confer a physiological (functional) 
benefit. A placebo effect is a physical or emotional 
change that is not the result of any physiological 
action of the treatment. The change may be beneficial 
in the short term and reflects the expectations of the 
participant and/or the investigators providing the 
treatment (also see bias). A placebo drug or “sham” 
surgery can remove this issue.
Plasticity: refers to changes that occur in the 
organization of the brain and spine. Neuroplasticity 
can be either positive (functional recovery) or 
negative (autonomic dysreflexia or neuropathic 
pain). Experiments have demonstrated that active 
rehabilitation programs improve neuroplasticity 
with the physical and occupational training. A 
common and surprising consequence of plasticity 
is that the location of a given function can “move” 
from one location to another in the brain or spinal 
cord due to repeated training after traumatic injury. 
The concept of plasticity can be applied to molecular 
and functional events. The phenomenon itself is 
complex and involves many levels of organization. 
The main thing is the adult brain and spine are not 
“hard-wired” with fixed and immutable structure. 
There is evidence that formation of new nerve cells 
occurs in the adult human brain and spinal cord.
Quadriplegia: see Tetraplegia
RCT or randomized control trial: a clinical trial in 
which the subjects enrolled are randomly assigned 
to either the experimental treatment arm (group) 
or control study arm of the trial. It is the preferred 
clinical trial protocol to be used in all pivotal clinical 
trial phases (e.g., Phase 3 trials). Well-designed 
RCTs minimize the influence of variables other than 
the intervention that might affect trial outcomes. 
For this reason, they provide the best evidence of 
efficacy and safety.
Sensory score: based on the ISNCSCI assessment 
of the patient’s perception of sensation from the 
skin of the body. The sensory score is calculated 
by testing a point on the skin surface associated 
with each spinal level from C2 to S4-5. This is done 
for both light touch and pinprick sensation and in 
comparison with sensations perceived from the 
skin above the level of spinal cord injury, such as 
the face. Each point is assigned a score of 0 (absent 
sensation), 1 (impaired or abnormal sensation), or 2 
(normal sensation). This gives a possible maximum 
score of 56 on each side, for a maximum total of 112 
each for light touch and pin prick. 
Sensory level: is defined as the spinal segment 
corresponding with the most caudal area having 
a normal score of 2/2 for both pin prick and light 
touch.
Spinal Cord Independence Measure: (or SCIM) 
a scale for assessing function and activities of daily 
life that appears to be better than the Functional 
Independence Measure (FIM) for assessing SCI. 
SCIM has now gone through a few iterations 
(currently in version 3). The SCIM is a 100-point 
disability scale developed specifically for SCI with 
emphasis on 17 activities associated with:
1. Self-care (feeding, bathing, dressing, grooming) 
max. = 20 points.
2. Respiration & sphincter management (breathing, 
bladder, bowel, use of toilet) max. = 40 points.
3. Mobility (in bed, transfers, indoors and outdoors, 
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Spinal decompression: a surgery to relieve 
pressure on the spinal cord (or nearby nerves) to 
prevent further tissue damage and other structural 
complications.
Sham operation/procedure: a surgical procedure in 
which the subject is operated on but does not receive 
the experimental intervention. Like a drug placebo 
treatment, this is done to keep trial assessors from 
knowing who received the treatment, so the surgery 
may be only superficial to give an appearance that 
the intervention was given.
Tetraplegia: (also known as quadriplegia) refers to 
loss of motor and/or sensory function in all four 
limbs due to spinal cord damage, with impairment 
of the upper extremities as well as trunk, legs, and 
pelvic organs. This implies damage to the cervical 
spinal cord (at or above the T1 level).
Zone of Partial Preservation (ZPP): only used 
when SCI is complete and refers to those segments 
below the neurological level of injury where there 
is some preservation of impaired motor or sensory 
function (usually, but not always, within a few 
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